# RegCell: Research, Emeryville, United States

> RegCell: RegCell is a biotechnology company founded in 2016 that specializes in developing cell-based immunotherapies focused on regulatory T cells (Tregs).

Source: https://millionrounds.com/startup/regcell (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# RegCell

RegCell is a biotechnology company founded in 2016 that specializes in developing cell-based immunotherapies focused on regulatory T cells (Tregs).

Funding reported Last round: Undisclosed round

Research Emeryville, United States

Company summary

- **Founded:** 2016 10 years old
- **Team:** 11 11 to 50 people
- **Funding reported:** $641M in dollars
- **Last round:** Undisclosed round Aug 2017

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for RegCell has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About RegCell

RegCell is a biotechnology company founded in 2016 that specializes in developing cell-based immunotherapies focused on regulatory T cells (Tregs).

The company aims to restore immune tolerance, particularly for autoimmune diseases and transplantation. Originally a university spinout in Japan, RegCell has since relocated its headquarters to the United States to enhance its global development efforts. The company's primary offering is a proprietary cell-therapy platform known as S/F-Epigen-Tregs, which creates disease-antigen-specific regulatory T cells. This innovative approach is designed to ensure the stability and functionality of Tregs in vivo. Additionally, RegCell is exploring cytotoxic T-cell therapies for cancer, including approaches derived from induced pluripotent stem cells (iPS). The company is actively engaged in research across various immune-regulation disorders, including graft-versus-host disease, allergies, and oncology.

## What company datasets say RegCell raised

Funding, as reported

Reported in all **$641M** in dollars

Rounds **2**

Last round **Undisclosed round**

Last round size **$3.1M**

Last round date **Aug 2017**

Investors listed **8**

## The company, in detail

What they build

Known for

biotechnology research b2b

Built with from their website

WordPress.org HREF Lang Sakura Internet Viewport Meta Google Font API Microsoft Exchange Bunny Fonts PrimeNG Microsoft 365 Apps & Services Mobile Friendly

+8 more

Multilingual Open Graph jQuery jQuery CDN WebFactory Maintenance Wordpress Microsoft Exchange Online Polyfill

- **Sector:** Research
- **Industry code:** NAICS 541714
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/regcell)

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put RegCell in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)